Argenx Lifts 2026 R&D And Sales Spending To About $4 Billion, Warns Against Assuming Another 45% Jump
The CFO said Forte accounts for roughly half of the higher budget and that fuller guidance is coming at the JPMorgan conference.
Argenx now expects combined research and sales-and-administrative spending of about $4 billion in 2026, CFO Karl Gubitz said on the company's third-quarter earnings call Thursday, a 45% increase from 2025. He told analysts not to carry that pace into next year.
Where the extra money goes
Argenx, which develops antibody-based medicines for autoimmune diseases, ties its budget to the Forte acquisition, Gubitz said, responding to a BNP Paribas analyst. Forte accounts for about half of the increase versus what the Street had expected: the $150 million of transaction costs already booked in the third quarter, plus roughly $50 million of operating costs for the celiac candidate FB102 over the rest of the year.
The rest, he said, covers commercial buildout in myositis and rheumatology after the positive Alkivia results, and work such as manufacturing and inventory for 10 assets in the clinic.
"Please do not assume another 45% increase into 2027," Gubitz said, adding that JPMorgan's healthcare conference would bring better guidance. Asked by a Goldman Sachs analyst about formal 2027 guidance, he said the company would probably give more clarity on expenses but probably not on revenue, citing binary events that complicate a revenue forecast.
A $1.7 billion quarter, 37% margin ex-Forte
Third-quarter product net sales were $1.7 billion, up 54% from a year earlier and 13% from the second quarter. The US contributed $1.5 billion, Japan $81 million and the rest of the world $158 million, with $11 million from product supply to Zai Lab in China.
Total operating expenses were $1.3 billion, and operating profit was $486 million, a 28% margin. Excluding the Forte transaction costs, Gubitz said, the margin was 37%. The company ended the quarter with $3.7 billion in cash and financial assets after paying a net $2.1 billion for Forte.
One drug becoming a platform
CEO Karen Massey said 2027 could bring five potential US launches, and that management is on track for its Vision 2030 targets. Among them: pediatric myasthenia gravis, with an FDA target decision date in February 2027; ocular myasthenia gravis; an autoinjector for Vyvgart Hytrulo in the second half of 2027; and a myositis filing by year-end.
Results from a late-stage head-to-head trial of empasiprubart against IVIG in multifocal motor neuropathy are due in December. Massey said that if the data are positive, the company plans to seek priority review.
Argenx plans to lay out a fuller expense picture at the JPMorgan conference early next year, and the empasiprubart trial results arrive in December.
Sources
- argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sa... — benzinga.com
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update – Company Announcement - FT.com — Financial Times
- argenx T3 BPA de 7,80 $ manque l’estimation de 7,83 $, le chiffre d’affaires de 1,751 Md $ dépasse l’estimation de 1,664 Md $1 min de lecture — fr.benzinga.com
- argenx SE (ARGX) stock price, news, quote and history - Yahoo Finance — Yahoo Finance
- argenx Reports Third Quarter 2026 Financial Results and — globenewswire.com